Pfizer Reports Fourth-Quarter and Full-Year 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Pfizer (PFE) Tops Q4 EPS by 20c, Revenue Misses, Guidance Falls Short of Views
February 8, 2022 6:48 AM ESTPfizer (NYSE: PFE) reported Q4 EPS of $1.08, $0.20 better than the analyst estimate of $0.88. Revenue for the quarter came in at $23.8 billion versus the consensus estimate of $24.17 billion.
GUIDANCE:
Pfizer sees FY2022 EPS of $6.35-$6.55, versus the consensus of $6.65. Pfizer sees... More
